SUNNYVALE, Calif., Oct. 3, 2023
/PRNewswire/ -- Willow Biosciences Inc.,
("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA
today jointly announced execution of a collaboration agreement for
a cell line productivity optimization development program for
manufacturing a large volume anti-infective Active Pharmaceutical
Ingredient ("API") through precision fermentation. Through the
partnership, SUANFARMA will have access to Willow's proprietary
strain optimization technologies to develop a more cost-effective
production process.
SUANFARMA has engaged Willow to apply its strain engineering
technology platform to enable more cost-effective commercial
production of the API at SUANFARMA's manufacturing site.
"We are pleased to further expand our successful relationship
with SUANFARMA, to bring sustainably sourced products to market by
leveraging our joint capabilities and their proven efficient
manufacturing resources," said Chris Savile, Willow's President &
CEO. "Together, we see a number of opportunities to create
alternative means to more sustainably produce key products for
better human health and wellness and we look forward to working
with the SUANFARMA team."
"SUANFARMA CDMO is delighted to further extend our
partnership with Willow toward developing commercial products to
broaden our portfolio by maximizing product quality at reduced cost
through fermentation technology," said Daniel Rivero, Industrial Director of
SUANFARMA. "Following successful development, we look
forward to bringing these life-enhancing products to market at
industrial scale through our manufacturing site in Europe. SUANFARMA CDMO
provides Contract Development and
Manufacturing Organization services to the market, with solid track
record and expertise in fermentation, purification, and chemical
synthesis technologies under the highest standards of quality for
the pharmaceutical and biotech industry."
SUANFARMA CDMO offers a comprehensive approach to
Technology Transfer, aiming to reduce risks and enhance success
within their global project management strategy. Our platform,
known as TT&GO®, employs a systematic and
quality-based methodology that leverages our expertise in GMP
manufacturing. This approach ensures efficient industrialization of
processes and thus swift market commercialization of the final
product.
In March 2023, Willow and
SUANFARMA announced an alliance with the intention to work together
on existing pharma and biotechnological capabilities for synthetic
molecules including anti-infectives and other APIs and
intermediates for Pharma and natural ingredients designed for the
Health & Wellness and Food & Beverage industries. Today's
announcement marks further progress in broadening the relationship
by offering an end-to-end synthetic biology solution and expanding
the parties' joint product portfolio.
About WILLOW BIOSCIENCES
Willow develops and produces precision fermented functional
ingredients for the health and wellness, food and beverage and
personal care markets. Willow's FutureGrown™ and BioOxi™ platforms
enable large-scale production with sustainability at its core.
About SUANFARMA
SUANFARMA founded in 1993, is a B2B life science partner
specialized in the development, production, and commercialization
of ingredients for the pharmaceutical, veterinary and nutraceutical
industries.
Our CDMO division provides integrated, end-to-end solutions for
development and commercialization services of intermediates and
drug substances for complex small molecules. We specialize helping
pharmaceutical, biotech and healthcare companies delivering full
integrated services that compress timelines to market maximizing
success.
Logo -
https://mma.prnewswire.com/media/2234752/Suanfarma_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/willow-and-suanfarma-announce-collaboration-on-development-of-large-volume-anti-infective-api-through-precision-fermentation-301942333.html